Table 1. Prevalence and rate of reversion of RT mutations at baseline (BL), 2 months (2mo) and 4 months (4mo) Structured Treatment Interruption (STI) and associated changes in Replication Capacity (RC).

	Prevalence baseline	Prevalence 2 months	Prevalence 4 months	% reversionBL-2mo	% reversion2mo–4mo	% reversionBL–4mo	RC gaina
E44D	26.2	22.6	22.6	14	5	18.2	90
T69D	21.4	16.7	14.3	22	14	33.3	76
108I	21.4	16.7	8.3	28	46	61.1	58
181C	39.3	36.9	28.6	9	33	39.4	57
184V	69.0	41.7	19	40	57	74.1	53.5
67N	57.1	42.9	31	27	26	45.8	51.25
219Q	17.9	15.5	8.3	20	50	60.0	50
118I	41.7	29.8	25	29	24	42.9	48
103N	53.6	36.9	21.4	36	41	62.2	45
215F	26.2	15.5	10.7	41	38	63.6	41
70R	22.6	21.4	14.3	32	46	63.2	39.75
41L	73.8	51.2	38.1	32	29	50.0	36
215Y	66.7	52.4	38.1	23	30	44.6	34
210W	54.8	44	36.9	22	14	32.6	30
74V	34.5	22.6	11.9	34	58	72.4	29
100I	14.3	11.9	6	17	50	58.3	16.8
190A	21.4	20.2	14.3	11	38	44.4	15.55

^a: RC gain was defined as the difference in median RC between the viruses who showed the reversion of a given mutation and the viruses who kept the mutation between baseline and 2 months STI.

The prevalence of each mutation decreased over the course of the STI. The last column of the table represents the difference between the median ΔRC of the samples which reverted a mutation back to wild-type codon and the median ΔRC of the samples which did not revert the mutation. Most mutation reversions were associated with an increase in RC over the course of the STI. The largest increase in RC occurred between baseline and 2 months of STI. Between 2 months and 4 months of STI, the reversion of mutations was also associated with an increase in RC, although of a lesser magnitude since RC was already close to 100% at 2 months (data not shown).